BACKGROUND: Blood pressure (BP) control among coronary artery disease patients remains suboptimal in clinical practice, potentially due to gaps in treatment intensification and medication adherence. However, longitudinal studies evaluating these relationships and outcomes are limited. METHODS AND RESULTS: We assessed BP trajectories among health maintenance organization patients with hypertension and incident coronary artery disease. BP trajectories were modeled over the year after coronary artery disease diagnosis, stratified by target BP goal. Treatment intensification (increase in BP therapies in the setting of an elevated BP), medication adherence (percentage of days covered with BP therapies), and outcomes (all-cause mortality, myocardial infarction, and revascularization) were evaluated in multivariable models: 9569 patients had a <140/90 mm Hg BP target and 12,861 had a <130/80 mm Hg BP target. Within each group, 4 trajectories were identified: good, borderline, improved, and poor control. After adjustment, increasing BP treatment intensity was significantly associated with better BP trajectories in both groups. Medication adherence had inconsistent effects. There were no significant differences in combined outcomes by BP trajectory, but among the diabetes and renal disease cohort, borderline control patients were less likely to have myocardial infarction (odds ratio, 0.61; 95% confidence interval, 0.40-0.93), and good control patients were less likely to have myocardial infarction (odds ratio, 0.53; 95% confidence interval, 0.34-0.84) or a revascularization procedure (odds ratio, 0.66; 95% confidence interval, 0.47-0.93) compared with poor control patients. CONCLUSIONS: In this health maintenance organization population, treatment intensification but not medication adherence significantly affects BP trajectories in the year after coronary artery disease diagnosis. Better BP trajectories are associated with lower rates of myocardial infarction and revascularization.
BACKGROUND: Blood pressure (BP) control among coronary artery diseasepatients remains suboptimal in clinical practice, potentially due to gaps in treatment intensification and medication adherence. However, longitudinal studies evaluating these relationships and outcomes are limited. METHODS AND RESULTS: We assessed BP trajectories among health maintenance organization patients with hypertension and incident coronary artery disease. BP trajectories were modeled over the year after coronary artery disease diagnosis, stratified by target BP goal. Treatment intensification (increase in BP therapies in the setting of an elevated BP), medication adherence (percentage of days covered with BP therapies), and outcomes (all-cause mortality, myocardial infarction, and revascularization) were evaluated in multivariable models: 9569 patients had a <140/90 mm Hg BP target and 12,861 had a <130/80 mm Hg BP target. Within each group, 4 trajectories were identified: good, borderline, improved, and poor control. After adjustment, increasing BP treatment intensity was significantly associated with better BP trajectories in both groups. Medication adherence had inconsistent effects. There were no significant differences in combined outcomes by BP trajectory, but among the diabetes and renal disease cohort, borderline control patients were less likely to have myocardial infarction (odds ratio, 0.61; 95% confidence interval, 0.40-0.93), and good control patients were less likely to have myocardial infarction (odds ratio, 0.53; 95% confidence interval, 0.34-0.84) or a revascularization procedure (odds ratio, 0.66; 95% confidence interval, 0.47-0.93) compared with poor control patients. CONCLUSIONS: In this health maintenance organization population, treatment intensification but not medication adherence significantly affects BP trajectories in the year after coronary artery disease diagnosis. Better BP trajectories are associated with lower rates of myocardial infarction and revascularization.
Authors: Michele Heisler; Mary M Hogan; Timothy P Hofer; Julie A Schmittdiel; Manel Pladevall; Eve A Kerr Journal: Circulation Date: 2008-05-27 Impact factor: 29.690
Authors: P Michael Ho; David J Magid; Susan M Shetterly; Kari L Olson; Thomas M Maddox; Pamela N Peterson; Frederick A Masoudi; John S Rumsfeld Journal: Am Heart J Date: 2008-04 Impact factor: 4.749
Authors: P Michael Ho; Chan Zeng; Heather M Tavel; Joe V Selby; Patrick J O'Connor; Karen L Margolis; David J Magid Journal: Arch Intern Med Date: 2010-05-24
Authors: Peter M Rothwell; Sally C Howard; Eamon Dolan; Eoin O'Brien; Joanna E Dobson; Bjorn Dahlöf; Peter S Sever; Neil R Poulter Journal: Lancet Date: 2010-03-13 Impact factor: 79.321
Authors: Thomas Weber; Irene Lang; Robert Zweiker; Sabine Horn; Rene R Wenzel; Bruno Watschinger; Jörg Slany; Bernd Eber; Franz Xaver Roithinger; Bernhard Metzler Journal: Wien Klin Wochenschr Date: 2016-06-09 Impact factor: 1.704
Authors: Stacie L Daugherty; J David Powers; David J Magid; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Julie A Schmittdiel; P Michael Ho Journal: Hypertension Date: 2012-06-25 Impact factor: 10.190
Authors: Paul Muntner; Jewell H Halanych; Kristi Reynolds; Raegan Durant; Suma Vupputuri; Victor W Sung; James F Meschia; Virginia J Howard; Monika M Safford; Marie Krousel-Wood Journal: J Clin Hypertens (Greenwich) Date: 2011-04-22 Impact factor: 3.738
Authors: Elizabeth H B Lin; Michael Von Korff; Paul Ciechanowski; Do Peterson; Evette J Ludman; Carolyn M Rutter; Malia Oliver; Bessie A Young; Jochen Gensichen; Mary McGregor; David K McCulloch; Edward H Wagner; Wayne J Katon Journal: Ann Fam Med Date: 2012 Jan-Feb Impact factor: 5.166
Authors: Irene V Blair; John F Steiner; Rebecca Hanratty; David W Price; Diane L Fairclough; Stacie L Daugherty; Michael Bronsert; David J Magid; Edward P Havranek Journal: J Gen Intern Med Date: 2014-02-19 Impact factor: 5.128
Authors: Robina Josiah Willock; Joseph B Miller; Michelle Mohyi; Ahmed Abuzaanona; Meri Muminovic; Phillip D Levy Journal: Curr Hypertens Rep Date: 2018-01-29 Impact factor: 5.369
Authors: Patrick J O'Connor; David J Magid; JoAnn M Sperl-Hillen; David W Price; Stephen E Asche; William A Rush; Heidi L Ekstrom; David W Brand; Heather M Tavel; Olga V Godlevsky; Paul E Johnson; Karen L Margolis Journal: BMJ Qual Saf Date: 2014-09-16 Impact factor: 7.035